Assessment of Brain Kappa Opioid Receptor Occupancy After Single Oral Doses of LY2456302 as Measured by PET With Radioligand LY2879788 in Healthy Subjects

NCT01232439 Phase 1 COMPLETED

To measure the occupancy of brain kappa opioid receptors after single oral doses of LY2456302.

Details

Lead sponsor	Eli Lilly and Company
Phase	Phase 1
Status	COMPLETED
Enrolment	13
Start date	2010-12
Completion	2011-04

Conditions

• Alcohol Dependence

Interventions

• opioid receptor kappa antagonist

Primary outcomes

• Change in brain kappa opioid receptor occupancy (RO) by positron emission tomography (PET) — Baseline, after single dose of study drug

Countries

United States